Drugs / intravenous immunoglobulins
intravenous immunoglobulins
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01360658 | Jun 2011 → Jun 2013 | solar urticaria | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01537575 | Jan 2008 → Dec 2009 | postpoliomyelitis syndrome | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00522821 | Nov 2007 → Jul 2014 | infectious disease, selective IgG subclass deficiency | Prothya Biosolutions | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02201576 Comparator | Feb 2015 → Jul 2020 | chronic transplant rejection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT04968899 Comparator | Apr 2022 → Apr 2025 overdue | autoimmune thrombocytopenia | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT00949065 Comparator | Aug 2009 → Jan 2011 | complex regional pain syndrome type 1 | University of Giessen | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00949065 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin therapy” NCT00522821 ↗ |
| Route | Intravenous | “intravenous immunoglobulin therapy” NCT00522821 ↗ |